BioCardia, Inc. (BCDA) research

BioCardia, Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $1.04
As of: 2026-10-02

BioCardia, Inc. (BCDA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.

As of 2026-10-01, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for BCDA. Method and limitations.

COMPANY DOSSIER

See the full BCDA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for BCDA on one page. Preview it with sample data, then open it live with a free account.

Preview the BCDA dossier

Active signals for BCDA

mediumEARNINGS_BEAT2026-08-16
Q2-2026: Beat consensus by 29.2%, EPS $-0.13 vs $-0.1836 estimate
All 2026-08-16 signals →
highINSTITUTIONAL_EXIT2026-08-16
CITADEL ADVISORS LLC cut 76% of BCDA (2026Q2)
All 2026-08-16 signals →
mediumNEW_POSITION2026-07-24
RENAISSANCE TECHNOLOGIES LLC new position in BCDA
All 2026-07-24 signals →
mediumEARNINGS_BEAT2026-06-15
Beat consensus by 21.6% - EPS $-0.4 vs $-0.51 estimate
All 2026-06-15 signals →
mediumEARNINGS_BEAT2026-06-15
Q4-2025: Beat consensus by 65.4% - EPS $-0.06 vs $-0.1734 estimate
All 2026-06-15 signals →

FREE, NO ACCOUNT

Every signal on BCDA, as it fires

You are seeing 5 of 6 signals recorded on BCDA since 2026-06-15.

The five above landed across 3 days. The other 1 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in BCDA (2026Q2)

Manager / security	Market value	% portfolio	QoQ
CITADEL ADVISORS LLCCUSIP 09060U606 · 2026Q2	$28K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, BCDA

8-K2026-10-01
SEC EDGAR ↗
8-K2026-09-23
SEC EDGAR ↗
8-K2026-09-21
SEC EDGAR ↗
8-K2026-09-10
SEC EDGAR ↗
8-K2026-08-24
SEC EDGAR ↗
8-K2026-08-21
SEC EDGAR ↗
8-K2026-08-12
SEC EDGAR ↗
10-Q2026-08-12
SEC EDGAR ↗
8-K2026-06-18
SEC EDGAR ↗
8-K2026-06-12
SEC EDGAR ↗

BCDA against its peers

BCDA's return on equity of -919.3% ranks in the 3rd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.

Metric	BCDA	Peer median	Percentile	n
Revenue FY	0.0 USD	1.0M USD	8	11
Operating margin	n/a	-1151.1%	n/a	10
Net margin	n/a	-1142.6%	n/a	10
Return on equity	-919.3%	-115.6%	3	18

Peers (21): CYCN, KTTA, ALLR, LSTA, PASG, ICU, DARE, NCEL, PTN, LPCN, CLRB, HIND, INTI, SYBX, ACTU, TVRD, LTRN, TPST, CKDXF, KPTI, SNSE. Left out: CTXR (no annual filing), FNCHQ (period gap), HOOK (period gap), ZIVO (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BCDA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more BCDA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BCDAand get the insider, 13F, options, and confluence read in one view.